Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
95-024
Phase 2 mab completed
Quick answer
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) for EBV-induced Lymphomas is a Phase 2 program (mab) at Atara Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Atara Biotherapeutics
- Indication
- EBV-induced Lymphomas
- Phase
- Phase 2
- Modality
- mab
- Status
- completed